Page 21 of 44.
A comprehensive clinical and harm-reduction guide to Baclofen in India, exploring its GABA-B mechanism, its role in treating cerebral palsy and spinal cord injuries, Jan Aushadhi pricing, and the life-threatening risk of abrupt withdrawal as of 2026.
A comprehensive clinical and harm-reduction guide to Tizanidine (Sirdalud) in India, exploring its unique alpha-2 adrenergic mechanism, Jan Aushadhi pricing, its role in treating MS spasticity, and the risk of rebound hypertension as of 2026.
A comprehensive clinical and harm-reduction guide to Chlorzoxazone (Mobizox) in India, exploring its mechanism, combination therapy protocols, Jan Aushadhi pricing, and the harmless 'orange urine' effect as of 2026.
A comprehensive clinical and harm-reduction guide to Methylphenidate (Inspiral/Addwize) in India, exploring its dopamine-reuptake mechanism, Schedule X regulations, Jan Aushadhi pricing, and the 2026 supply crisis.
A comprehensive clinical and harm-reduction guide to Modafinil (Modalert) in India, exploring its dopamine-transport mechanism, the 'nootropic' misuse trend among professionals, Jan Aushadhi pricing, and the risk of Stevens-Johnson Syndrome as of 2026.
A comprehensive clinical and harm-reduction guide to Pseudoephedrine in India, exploring its sympathomimetic mechanism, its classification as an NDPS Controlled Substance, Jan Aushadhi pricing, and the risk of methamphetamine diversion as of 2026.
A deep dive into Tapentadol Hydrochloride, exploring its NRI mechanism, Indian market pricing, comparison with Tramadol, and its rising profile in non-medical use as of 2026.
A comprehensive clinical and harm-reduction guide to Sibutramine in India, detailing its 2010 ban, its illegal detection in 'natural' supplements, the severe cardiovascular risks, and the 2026 crackdown on illicit diet pills.
A comprehensive clinical and harm-reduction guide to Ketamine in India, exploring its NMDA-receptor antagonism, its classification as a Schedule X/NDPS psychotropic, Jan Aushadhi pricing, the 'K-Hole' phenomenon, and the 2026 club drug trends.
A comprehensive clinical and harm-reduction guide to Dextromethorphan (DXM) in India, exploring its NMDA-receptor antagonism, the four plateaus of dissociation, Jan Aushadhi pricing, and the 2026 CDSCO crackdown on cough syrup misuse.
A comprehensive clinical and harm-reduction guide to Nitrous Oxide (N2O) in India, exploring its NMDA-receptor antagonism, the hidden risk of permanent nerve damage, Jan Aushadhi (Institutional) pricing, and the 2026 'Whippet' party drug trend.
A comprehensive clinical and harm-reduction guide to Promethazine (Phenergan) in India, exploring its dopamine-blocking mechanism, its role in the 'Lean' cocktail, Jan Aushadhi pricing, and the risk of acute dystonia as of 2026.